Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Imaging is an increasingly important part of clinical medicine and contrast enhancement adds valuable diagnostic information. Prior to 2006 gadolinium based contrast agents (GBCA) were used in patients with kidney disease in an attempt to avoid the adverse consequences of iodinated contrast agents. The amount administered often exceeded the United States Food and Drug Administration (FDA)-recommended dosing. After the association between GBCA and nephrogenic systemic fibrosis (NSF) was reported, usage of GBCA was markedly reduced in patients with kidney disease. As a result, iodinated contrast was often used in place of GBCA. Recently, several studies showed that the risk of NSF using GBCA with increased thermodynamic and kinetic stability or increased relaxivity along with a restricted use policy has dramatically reduced NSF risk in patients with chronic kidney disease (CKD). We discuss the risks of GBCA and iodinated contrast use in different stages of CKD and suggest that in some situations GBCA use may pose less overall risk to the patient with advanced kidney disease.

Original languageEnglish (US)
Pages (from-to)480-486
Number of pages7
JournalSeminars in Dialysis
Volume24
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Nephrogenic Fibrosing Dermopathy
Gadolinium
Contrast Media
Kidney Diseases
Chronic Renal Insufficiency
Clinical Medicine
United States Food and Drug Administration
Thermodynamics

ASJC Scopus subject areas

  • Nephrology

Cite this

Gadolinium and Nephrogenic Systemic Fibrosis : Have We Overreacted? / Penfield, Jeffrey G.; Reilly, Robert F.

In: Seminars in Dialysis, Vol. 24, No. 5, 09.2011, p. 480-486.

Research output: Contribution to journalArticle

@article{1a475d8e834a47d6bccec6ab28d74050,
title = "Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?",
abstract = "Imaging is an increasingly important part of clinical medicine and contrast enhancement adds valuable diagnostic information. Prior to 2006 gadolinium based contrast agents (GBCA) were used in patients with kidney disease in an attempt to avoid the adverse consequences of iodinated contrast agents. The amount administered often exceeded the United States Food and Drug Administration (FDA)-recommended dosing. After the association between GBCA and nephrogenic systemic fibrosis (NSF) was reported, usage of GBCA was markedly reduced in patients with kidney disease. As a result, iodinated contrast was often used in place of GBCA. Recently, several studies showed that the risk of NSF using GBCA with increased thermodynamic and kinetic stability or increased relaxivity along with a restricted use policy has dramatically reduced NSF risk in patients with chronic kidney disease (CKD). We discuss the risks of GBCA and iodinated contrast use in different stages of CKD and suggest that in some situations GBCA use may pose less overall risk to the patient with advanced kidney disease.",
author = "Penfield, {Jeffrey G.} and Reilly, {Robert F.}",
year = "2011",
month = "9",
doi = "10.1111/j.1525-139X.2011.00945.x",
language = "English (US)",
volume = "24",
pages = "480--486",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Gadolinium and Nephrogenic Systemic Fibrosis

T2 - Have We Overreacted?

AU - Penfield, Jeffrey G.

AU - Reilly, Robert F.

PY - 2011/9

Y1 - 2011/9

N2 - Imaging is an increasingly important part of clinical medicine and contrast enhancement adds valuable diagnostic information. Prior to 2006 gadolinium based contrast agents (GBCA) were used in patients with kidney disease in an attempt to avoid the adverse consequences of iodinated contrast agents. The amount administered often exceeded the United States Food and Drug Administration (FDA)-recommended dosing. After the association between GBCA and nephrogenic systemic fibrosis (NSF) was reported, usage of GBCA was markedly reduced in patients with kidney disease. As a result, iodinated contrast was often used in place of GBCA. Recently, several studies showed that the risk of NSF using GBCA with increased thermodynamic and kinetic stability or increased relaxivity along with a restricted use policy has dramatically reduced NSF risk in patients with chronic kidney disease (CKD). We discuss the risks of GBCA and iodinated contrast use in different stages of CKD and suggest that in some situations GBCA use may pose less overall risk to the patient with advanced kidney disease.

AB - Imaging is an increasingly important part of clinical medicine and contrast enhancement adds valuable diagnostic information. Prior to 2006 gadolinium based contrast agents (GBCA) were used in patients with kidney disease in an attempt to avoid the adverse consequences of iodinated contrast agents. The amount administered often exceeded the United States Food and Drug Administration (FDA)-recommended dosing. After the association between GBCA and nephrogenic systemic fibrosis (NSF) was reported, usage of GBCA was markedly reduced in patients with kidney disease. As a result, iodinated contrast was often used in place of GBCA. Recently, several studies showed that the risk of NSF using GBCA with increased thermodynamic and kinetic stability or increased relaxivity along with a restricted use policy has dramatically reduced NSF risk in patients with chronic kidney disease (CKD). We discuss the risks of GBCA and iodinated contrast use in different stages of CKD and suggest that in some situations GBCA use may pose less overall risk to the patient with advanced kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=80054678346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054678346&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2011.00945.x

DO - 10.1111/j.1525-139X.2011.00945.x

M3 - Article

C2 - 21913988

AN - SCOPUS:80054678346

VL - 24

SP - 480

EP - 486

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 5

ER -